{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:46:28Z","timestamp":1783734388112,"version":"3.55.0"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Facial Plast Surg"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Botulinum toxins (BoNT) are complex biological products. Each licensed BoNT type A (BoNTA) has its own individual characteristics resulting into different attributes, some of them being of clinical relevance. Besides profound anatomical knowledge and understanding of esthetic principles, the responsible injecting physician should be aware of those pharmaceutical and clinical properties. Especially against the background of new BoNTA formulations receiving approval by the authorities, a critical and dedicated discussion on the individual characteristics should take place, and the potential relevance on the treatment outcome should be taken into consideration.<\/jats:p>","DOI":"10.1055\/a-1730-8270","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:03:05Z","timestamp":1641340985000},"page":"152-155","source":"Crossref","is-referenced-by-count":4,"title":["Botulinum Toxins for Esthetic Facial Injections: A Scientific Review to Support Evidence-Based Best Practice"],"prefix":"10.1055","volume":"38","author":[{"given":"Wolfgang G.","family":"Philipp-Dormston","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, University Witten\/Herdecke, Witten, Germany"},{"name":"Department of Dermatology and Dermatologic Surgery, Hautzentrum Koeln, Klinik Links vom Rhein, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bertossi","sequence":"additional","affiliation":[{"name":"Maxillo Facial Plastic Surgery Unit, Department of Surgery, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khosrow","family":"Houschyar","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Hautzentrum Koeln, Klinik Links vom Rhein, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eqram","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Royal Free Hospitals & University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.2010.1937","article-title":"Terminology for preparations of botulinum neurotoxins: what a difference a name makes","volume":"305","author":"A Albanese","year":"2011","journal-title":"JAMA"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.11138\/FNeur\/2018.33.1.007","article-title":"Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal","volume":"33","author":"A Ferrari","year":"2018","journal-title":"Funct Neurol"},{"key":"ref3","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"M F Brin","year":"2014","journal-title":"Biologics"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2710.2007.00835.x","article-title":"Comparing two botulinum toxin type A formulations using manufacturers' product summaries","volume":"32","author":"R Wenzel","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00105-013-2744-5","article-title":"Botulinum toxin in dermatology [in German]","volume":"65","author":"W G Philipp-Dormston","year":"2014","journal-title":"Hautarzt"},{"issue":"11","key":"ref6","first-page":"719","article-title":"Potency equivalence of botulinum toxin preparations","volume":"87","author":"P Hambleton","year":"1994","journal-title":"J R Soc Med"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"M Naumann","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"issue":"13","key":"ref8","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/mds.25582","article-title":"Diffusion, spread, and migration of botulinum toxin","volume":"28","author":"J Ramirez-Castaneda","year":"2013","journal-title":"Mov Disord"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/WNF.0b013e31815cba8a","article-title":"Undesirable distant effects following botulinum toxin type a injection","volume":"31","author":"N Roche","year":"2008","journal-title":"Clin Neuropharmacol"},{"issue":"01","key":"ref10","first-page":"198","article-title":"Systemic adverse events after botulinum toxin A injections for management of lower limbs spasticity","volume":"20","author":"C Ko-Ko","year":"2006","journal-title":"Neurorehabil Neural Repair"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.clinthera.2007.07.020","article-title":"Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia","volume":"29","author":"M A Chapman","year":"2007","journal-title":"Clin Ther"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/14764172.2012.738913","article-title":"A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines","volume":"14","author":"M Moers-Carpi","year":"2012","journal-title":"J Cosmet Laser Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.toxicon.2019.07.005","article-title":"The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT\/A products","volume":"168","author":"A Kutschenko","year":"2019","journal-title":"Toxicon"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"e0256869","DOI":"10.1371\/journal.pone.0256869","article-title":"Safety verification for polysorbate 20, pharmaceutical excipient for intramuscular administration, in Sprague-Dawley rats and New Zealand White rabbits","volume":"16","author":"J Kim","year":"2021","journal-title":"PLoS One"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/asj\/sjab058","article-title":"Immunogenicity to botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications","volume":"42","author":"E Rahman","year":"2022","journal-title":"Aesthet Surg J"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2009.06.040","article-title":"Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants","volume":"61","author":"M F Brin","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"07","key":"ref18","first-page":"CD011301","article-title":"Botulinum toxin type A for facial wrinkles","volume":"7","author":"C P Camargo","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1524-4725.2011.02024.x","article-title":"Long-term treatment of glabellar rhytides using onabotulinumtoxina","volume":"37","author":"R A Dailey","year":"2011","journal-title":"Dermatol Surg"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/01.prs.0000279377.86280.8d","article-title":"Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study","volume":"120","author":"M A Stotland","year":"2007","journal-title":"Plast Reconstr Surg"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/asj\/sjx179","article-title":"Impact of comprehensive, minimally invasive, multimodal aesthetic treatment on satisfaction with facial appearance: the HARMONY study","volume":"38","author":"S H Weinkle","year":"2018","journal-title":"Aesthet Surg J"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/asj\/sjy239","article-title":"Aesthetic treatment positively impacts social perception: analysis of subjects from the HARMONY study","volume":"39","author":"S Dayan","year":"2019","journal-title":"Aesthet Surg J"}],"container-title":["Facial Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1730-8270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T10:23:54Z","timestamp":1660127034000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1730-8270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":21,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,6,12]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1730-8270","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0736-6825","1098-8793"],"issn-type":[{"value":"0736-6825","type":"print"},{"value":"1098-8793","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,4]]},"published":{"date-parts":[[2022,1,4]]}}}